Clinical Trial

Prediction of Atrial Fibrillation Using Polygenic Risk Score

Study acronym: PREGENCE
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn whether a genetic risk score can help identify undiagnosed atrial fibrillation (AF) in adults who may have it. AF is an irregular heartbeat that raises the risk of stroke if not treated early. The main questions it aims to answer are: Can a polygenic risk score (PRS) - a score based on a person's genes - identify who is more likely to have AF? Does combining PRS with a person's medical history predict AF better than using medical history alone? Participants will: Wear a continuous ECG patch for 7 days to record heart rhythm Give a blood sample for genetic testing to calculate their PRS Use a six-lead handheld ECG device (HATIV® P30, VUNO Inc., Seoul, Republic of Korea) to check their own heart rhythm at home once or twice a week for 1 year Visit the clinic 5 times over 1 year Researchers will use the genetic and clinical information collected to build a scoring system that predicts who is at risk for AF.
Trial Details
NCT Number NCT07641582
Lead Sponsor Seoul St. Mary's Hospital
Conditions Atrial Fibrillation (AF)
Enrollment 800 participants
Start Date 2024-11-19
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-11